GLP-1 analogues, when used as adjunctive therapy for asthma control in patients with comorbid obesity or T2DM, may represent a breakthrough in the treatment of this patient population. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.